Clene Submits NDA Seeking Accelerated Approval for ALS Drug

20 Oct 2026 0 comments

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

Source: NeurologyLive Published 20 Oct 2026 Imported 20 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment